On November 20, 2026, AtomVie Global Radiopharma, a contract development and manufacturing organization (CDMO) specializing in radiopharmaceuticals, announced a significant supply agreement with ITM Isotope Technologies Munich SE. The partnership focuses on the delivery of ITM's high-quality medical radioisotope, Lutetium-177 without carrier added (n.c.a. 177Lu). This strategic alliance is intended to bolster AtomVie’s capabilities in the development and manufacturing of radiopharmaceuticals while ensuring reliability in the supply chain.
The arrangement is especially vital for AtomVie’s partners in the field of precision oncology, providing enhanced access to this widely-used radioisotope. According to Bruno Paquin, AtomVie’s CEO, the company has been supporting multiple radiopharmaceutical enterprises requiring consistent, high-quality radioisotope supplies.
"Strengthening our collaboration with ITM, a world leader in isotope production, guarantees reliable access to n.c.a. 177Lu, facilitating therapeutic and diagnostic development programs,” Paquin stated. ITM’s n.c.a. 177Lu is designed to be linked to target molecules, directing the radioisotope precisely to tumor tissues. Here, this highly purified form of Lutetium-177 emits beta radiation, effectively destroying cancer cells while minimizing damage to surrounding healthy tissues.
ITM has filed a Drug Master File (DMF) for n.c.a. 177Lu with the U.S. Food and Drug Administration (FDA) and holds a license under the brand name EndolucinBeta® in the European Union. Dr. Andrew Cavey, CEO of ITM, expressed enthusiasm regarding the new partnership, highlighting its role in supporting companies focused on developing innovative radiopharmaceuticals. "The reliable supply of high-quality radioisotopes like Lutetium-177 is a priority for us. In collaboration with AtomVie and its network of developers, ITM is proud to contribute to more effective radiopharmaceutical therapies for cancer patients."
AtomVie Global Radiopharma is recognized as a pioneering CDMO committed to advancing the development and commercialization of radiopharmaceuticals. Its comprehensive offerings include the development of process and analytical methods, GMP-compliant manufacturing, quality control, regulatory support, and worldwide distribution services for clinical trial materials and commercially available drugs. The organization is dedicated to supporting pharmaceutical and biotechnology companies globally in the development of innovative radiotherapeutics and diagnostics, and is currently commissioning its new state-of-the-art facility in Hamilton, Ontario, spanning 72,300 square feet. More information can be found on their website at
www.atomvie.com.
On the other hand, ITM Isotope Technologies Munich SE is a leading biotechnology company focused on the field of radiopharmaceuticals. It aims to supply a new generation of radiopharmaceuticals for the treatment and diagnosis of hard-to-treat tumors, addressing the needs of cancer patients, healthcare professionals, and partners alike. ITM operates with the principle of enhancing patient benefits across all activities, advancing an extensive pipeline with several Phase-3 studies in precision oncology, combining its high-quality radioisotopes with various targeting molecules. With two decades of pioneering work in the field of radiopharmacy and a strong position in the industry, ITM is dedicated to supplying more effective targeted therapies that improve treatment outcomes and quality of life for patients. For more details, visit their website at
www.itm-radiopharma.com.
For media inquiries, AtomVie can be contacted through Tina Chainani at +1 905 912 4209, while ITM's corporate communications can be reached via Kathleen Noonan and Julia Westermeir at +49 89 329 8986 1500.